ReviewInnere Medizin (Heidelberg, Germany)2026
[Rheumatoid arthritis-more than just a joint disease : Overview for internal medicine practice].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a common chronic inflammatory disease and a systemic autoimmune disorder associated with increased morbidity and mortality due to multiorgan involvement.
objectivesTo summarize pathophysiology, clinical presentation, diagnostics and modern treatment strategies of RA, and to highlight its relevance for internal medicine.
methodsNarrative review of current literature, guidelines and clinical studies with a focus on clinically relevant aspects regarding diagnosis, treatment, and comorbidities.
resultsRA results from a complex interaction of genetic predisposition and immune dysregulation leading to autoantibody formation and chronic inflammation. Clinically, it typically presents as symmetric polyarthritis, although early and atypical manifestations are common. Diagnosis is primarily clinical and is supported by serology and imaging. Early treatment following a treat-to-target strategy with disease-modifying anti-rheumatic drugs (DMARDs) enables remission in many patients. Comorbidities, particularly cardiovascular disease, significantly contribute to disease burden.
conclusionRA requires early recognition, timely initiation of therapy, and interdisciplinary management. Internists play a key role in early diagnosis, risk stratification and long-term care.
Indexed as
Identifiers
42230348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.